Last reviewed · How we verify
Relistor Injectable Product
At a glance
| Generic name | Relistor Injectable Product |
|---|---|
| Also known as | Methylnaltrexone Bromide |
| Sponsor | Methodist Health System |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- RELISTOR's Effects on Opioid-Induced Constipation
- Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics (NA)
- Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Relistor Injectable Product CI brief — competitive landscape report
- Relistor Injectable Product updates RSS · CI watch RSS
- Methodist Health System portfolio CI